ACON:NSD-Aclarion Inc (USD)

COMMON STOCK | Health Information Services | NSD

Last Closing Price

USD 0.61

Change

0.00 (-0.05)%

Market Cap

USD 4.77M

Volume

7.54K

Avg Analyst Target

USD 3.00 (+392.05%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ACON Stock Forecast & Price:
Based on the Aclarion Inc stock forecasts from 1 analysts, the average analyst target price for Aclarion Inc is USD 3.00 over the next 12 months. Aclarion Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aclarion Inc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Aclarion Inc’s stock price was USD 0.61. Aclarion Inc’s stock price has changed by -27.42% over the past week, -37.79% over the past month and 0% over the last year.

About Aclarion Inc (ACON:NSD)

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate lev ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-08 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CHNG Change Healthcare Inc

N/A

USD9.03B N/A 16.98
INOV Inovalon Holdings Inc

N/A

USD6.37B 122.57 33.93
HQY HealthEquity Inc

-1.49 (-2.25%)

USD5.55B 789.30 56.63
TXG 10X Genomics Inc

+2.49 (+7.27%)

USD4.01B N/A -31.79
RCM R1 RCM Inc

+0.45 (+4.56%)

USD3.99B 79.75 30.92
PINC Premier Inc

-0.05 (-0.15%)

USD3.97B 21.17 11.27
ONEM 1Life Healthcare Inc

+0.05 (+0.30%)

USD3.42B N/A -12.15
HMSY HMS Holdings Corp

N/A

USD3.29B 47.40 23.59
PGNY Progyny Inc

+0.32 (+0.99%)

USD3.16B 87.36 144.85
CERT Certara Inc

+0.37 (+2.12%)

USD2.83B N/A 34.83

ETFs Containing ACON

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Health Information Services)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 4.77M 4% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Health Information Services)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.23 44% F 38% F
Price / Cash Flow Ratio -2.03 61% D- 56% F
EV/EBITDA -1.63 56% F 63% D
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 70.01% 92% A- 95% A
Return on Assets -108.06% 6% F 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.96 75% C 58% F
Short Percent 1.67% 73% C 56% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.